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SUMMARY – Epilepsy is the most common neurological complication in pregnancy. Women 
with epilepsy have a higher risk of complications in pregnancy. In Croatia, women with epilepsy are 
treated by neurologists at tertiary centers according to the place of residence. We prospectively 
 followed-up pregnancies in women with epilepsy and healthy controls, and analyzed the factors 
 responsible for their delivery outcomes and development of their babies. Healthy pregnant women 
had a higher level of education and economic status, but pregnant women with epilepsy took folic acid 
in a higher proportion than controls, possibly due to timely preconception counseling. Complications 
during pregnancy depended on the number of antiepileptic drugs and epilepsy control. We noticed 
some behavioral and cognitive aspects in children exposed in utero to valproic acid, which required 
follow up. Th e rate of congenital malformations was not increased. In conclusion, women with epi-
lepsy should receive preconception counseling about the risk for pregnancy, but also about the possi-
bilities to minimize that risk. We have introduced a model of integrative management of pregnancy 
and epilepsy based on close collaboration among diff erent clinical experts in Croatia, in order to 
 provide prompt counseling and timely intervention.
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Introduction
About 50 million people worldwide suff er from 
epilepsy, including women of fertile age. Epilepsy is 
the most common neurological complication in preg-
nancy. Women with epilepsy have a higher risk of 
complications in pregnancy as compared with healthy 
ones, e.g., the risk of hyperemesis gravidarum is almost 
twofold, preterm pregnancy threefold, hypertension in 
pregnancy-preeclampsia almost twofold, cesarean sec-
tion and placental rupture twofold to threefold, and 
perinatal mortality up to eight times greater1. Consid-
ering that 0.3%-0.6% of all pregnant women have epi-
lepsy and therefore 1 of 250 embryos/fetuses is ex-
posed to antiepileptic drugs (AEDs), it is worth eff orts 
of health professionals to try to improve the quality of 
management in such pregnancies2.
In general population, there is a 3%-4% risk of hav-
ing a child with major congenital anomaly. About 10% 
of these anomalies can be attributed to maternal drug 
intake, exposure to chemical substances, infections, or 
familial disease. Pregnant women with epilepsy are at 
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a higher risk of unfavorable outcome of pregnancy be-
cause of taking diff erent types of AEDs as potential 
teratogens, the possibility of epileptic seizure impair-
ment, genetic factors, and comorbidities2-4. Adverse 
AED eff ects on the embryo or fetus can present as fe-
tal loss, intrauterine growth retardation (IUGR), con-
genital malformations, impaired postnatal develop-
ment, and behavior problems.
Despite eff orts invested so far, some risk factors for 
unfavorable obstetric outcomes in women with epi-
lepsy remain inadequately understood. Complex met-
abolic and excretion interactions between the mother 
and the fetus in case of epilepsy are misbalanced due to 
the impact of AED on sex steroid levels and possible 
other disturbances of maternal homeostasis. Th ere are 
no suffi  cient studies of the impact of AED on the lev-
el of steroid hormones and non-steroids during preg-
nancy, delivery and puerperal period. Bag et al. com-
pared the sex steroid hormone levels during pregnancy 
between the groups with increased and not increased 
seizure frequency. Th e increased seizure group had sig-
nifi cantly higher estrogen levels, lower levels of pro-
gesterone, and lower levels of AEDs. In addition, the 
authors noted that patients having had abortions and 
those having developed epileptic status had high se-
rum estrogen levels5. Falling serum levels of progester-
one may be associated with increased seizure frequen-
cy, and may be most prevalent around parturition6.
Th ere is a higher risk of adverse eff ects in such 
pregnancies regardless of AED therapy, but it is most-
ly connected with AED intake. Th e risk is higher in 
longer duration and treatment of epilepsy. In pregnant 
women on monotherapy, the risk is 2.9% for lamotrig-
ine (LTG), carbamazepine (CBZ) and oxcarbazepine 
(OXC) to 7.2% for valproic acid (VPA)2,7,8. Th e risk is 
twice higher with the intake of 2 or more AEDs or 
with high AED concentration in plasma. Th e inci-
dence of malformations in children is highest (12.7%) 
in women taking more AEDs and having seizures dur-
ing pregnancy2,7,8. Preconception counseling is the 
process of planning and preparing for pregnancy and 
gaining optimal balance of physical, emotional and 
mental health before conception. In women with epi-
lepsy, preparing for pregnancy includes analysis of pre-
vious antiepileptic treatment in order to minimize the 
risk factors for both the fetus and the mother.
Patients with epilepsy in Croatia are usually treated 
in tertiary level centers by subspecialists (neurologists 
and pediatric neurologists) and women with epilepsy 
are referred by their primary care physicians to hospi-
tal according to the place of residence. Primary care 
practitioners follow the instructions from tertiary level 
specialists without active involvement in therapy 
switch. According to this issue, the greatest responsi-
bility is on the neurologist, who must be timely in-
formed about the possible pregnancy in order to adjust 
patient therapy.
Material and Methods
Th is article describes prospective surveillance of 
pregnant women with epilepsy from May 2003 till 
May 2013 at the Sestre milosrdnice University Hospi-
tal Center in Zagreb, Croatia. All data were obtained 
from women with epilepsy and their documentation 
during outpatient visits to the neurologist, gynecolo-
gist and pediatrician neurologist. Data collected on 
pregnant women included age, socio-demographic 
data (marital status, income and education), smoking 
habit, previous loss of pregnancy or children, parity, 
actual pregnancy planning, type of epilepsy, electroen-
cephalography (EEG) fi ndings, AED dosage before 
and during pregnancy, actual pregnancy data (folic 
acid intake, vitamin K, seizures during pregnancy, ul-
trasound (US) fi ndings and complications). Prenatal 
US and other relevant prenatal testing was performed 
as requested by the gynecologist or pediatrician/ge-
neticist (triple test, amniocentesis, etc.). Newborns 
were examined by pediatrician neurologist/geneticist 
at Clinical Department of Pediatrics and followed up 
yearly till school age. Data on newborns/children in-
cluded term/mode of delivery, Apgar score, body 
weight, body height, and early psychomotor develop-
ment. Results were compared with those in healthy 
control subjects. Detailed examination of the newborn 
included anthropometric measurements, clinical fea-
tures, if relevant, photos of dysmorphic features, search 
for minor and major anomalies, and yearly evaluation 
of neurological development. When needed, psycho-
logical testing was performed including evaluation of 
intellectual capacities in older children (Kohs, numeric 
factor, social functioning, dictionary, perceptive motor 
skills, motor velocity as measure of concentration, at-
tention span, Bender gestalt, etc.). All newborns un-
derwent screening for hearing. Other fi ndings were 
also included if needed (brain US, ECHO, abdominal 
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US, karyotyping, brain computed tomography (CT) or 
magnetic resonance imaging (MRI), vision, etc.).
Data on the control group were obtained from 
Clinical Department of Gynecology and Obstetrics 
and included age, socio-demographic data (marital 
status, income and education), pregnancy planning, 
smoking habit, previous loss of pregnancy or children, 
parity, actual pregnancy planning, actual pregnancy 
data (folic acid intake, vitamin K, US fi ndings, compli-
cations and pregnancy outcome). Mothers with chron-
ic diseases and smokers were excluded from the study. 
Data on newborns from the control group were col-
lected prospectively from Clinical Department of Gy-
necology and Obstetrics and Clinical Department of 
Pediatrics and included delivery term and mode, Ap-
gar score, body weight and body height. Examination 
of the newborns included anthropometric measure-
ments, clinical features, search for minor and major 
anomalies, and neurological evaluation.
Statistics
Statistical analysis was performed in Microsoft Of-
fi ce Excel 2010 program using XLSTAT add-on (ver. 
2011.5.01). Results were presented in tables or graphs, 
showing descriptive statistics parameters (mean, stan-
dard deviation and percentage). Mean values of mater-
nal and neonatal conditions and pregnancy outcomes 
were compared using the unpaired Student’s t-test for 
numeric variables with normally distributed values and 
Kolmogorov-Smirnov two-tailed test if otherwise. 
Distributions of categorical and ordinal variables were 
compared using the c2-test. Th e values of p≤0.05 were 
considered statistically signifi cant.
Standard protocol approvals, registrations 
and patient consents
Th e researchers contacted all women included and 
obtained their written consent prior to inclusion in the 
study. Th e study was approved by the Ethics Board of 
the Sestre milosrdnice University Hospital Center in 
Zagreb, and was performed in accordance with ethical 
standards laid down in the 1964 Declaration of Hel-
sinki.
Results
During the period from May 2003 till May 2013, 
we prospectively followed-up 74 pregnancies in wom-
en with epilepsy (group 1) and 147 healthy controls 
(group 2). Th e average age was 34 (22-39) years in 
group 1 and 36 (19-49) years in group 2 (p>0.05).
Socio-demographic status
Socio-demographic status of the two groups of 
pregnant women is shown in Table 1. Healthy preg-
nant women had a signifi cantly higher level of educa-
tion and economic status, whereas there was no be-
tween-group diff erence according to marital status 
(Table 1).
Smoking
Th e association of smoking and delivery outcome 
(premature delivery and spontaneous abortion) was 
evident in the group of women with epilepsy. Th ere 
were six smokers, of which three had early spontane-
ous abortions and one had premature delivery at 36 
weeks + 5 days. Control group of healthy women were 
non-smokers during pregnancy and there was no case 
of spontaneous abortion in this group.
Folic acid intake and preconception counseling 
of epileptic women
Healthy controls planned their pregnancy in a sig-
nifi cantly higher number of pregnancies (114/128 or 
89.06%) as compared to 35% (26/74) of women with 
epilepsy (Table 1). About 60% of pregnant women 
with epilepsy had received preconception counseling 
as compared to none in the control group and about 
20% of women with epilepsy took folic acid (FA) 
properly, as compared to only 2.7% in the control 
group (Table 1). Even more, pregnant women with 
epilepsy having attended preconception counseling 
had signifi cantly less spontaneous abortions and still-
births as compared to those not having received pre-
conception counseling (Fig. 1).
Antiepileptic therapy
Monitored women with epilepsy during pregnancy 
were prescribed diff erent types of AED: LTG, VPA, 
phenytoin (PHT), phenobarbitone (PB), gabapentin 
(GBP), topiramate (TPM), CBZ, clonazepam (CZP), 
and OXC. In 62 of 70 (88.6%) monitored pregnancies, 
women were on monotherapy: mostly (37/62) on 
LTG, 13/62 on CBZ, 6 on VPA, 3 on PB, 1 on OXC, 
2 on GBP, and 1 on PHT. Eight pregnancies (8/70 or 
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11.4%) were on polytherapy with the following com-
binations: TPM/VP, LTG/CBZ, CBZ/PB, TPM/
CBZ/PHT and VP/CZP. Four pregnant women were 
without AEDs.
Seizures
About 40% of women with epilepsy in our study 
had seizures during pregnancy. A higher proportion of 
women on polytherapy (63%) had seizures during 
pregnancy as compared to those on monotherapy 
(37%) (Table 2). None had status epilepticus during 
pregnancy. Th ere was no diff erence in the mode of de-
livery (vaginal or cesarean section) between the groups 
with epilepsy and healthy controls, but women with 
seizures during pregnancy delivered with cesarean sec-
tion more frequently than those without seizures. Th e 
AED dosage had to be increased in 53% of pregnan-
cies (50% on monotherapy and 75% on polytherapy) 
and to switch AED in 26% of pregnancies (23% on 
monotherapy and 50% on polytherapy) (Table 2).
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Mode of delivery and anthropometric measurements 
of neonates
When we cut out women with early spontaneous 
abortions in the epileptic group, there was no statisti-
cal diff erence in the mode of delivery between the con-
trol and epileptic women. In each group, 25% of wom-
en had cesarean section performed (25% or 36/147 vs. 
25% or 16/64). Th ere were no statistical diff erences in 
neonatal birth length or birth weight between the 
women with epilepsy and healthy controls, except for 
the group under 500 g, due to stillbirths/spontaneous 
abortions in mothers with epilepsy. Th e neonates of 
healthy controls had a signifi cantly better Apgar score 
(p=0.004; D=0.205) (Table 3).
Adverse eff ects on embryo or fetus
Healthy controls had a signifi cantly lower number 
of complications in pregnancy (p<0.0001; D=0.246). 
Furthermore, when we compared women with epilep-
sy according to the number of AEDs, about 40% of 
pregnancies on AED polytherapy resulted in various 
complications as compared to 20% of pregnancies on 
AED monotherapy (Table 4). Moreover, monitoring 
of pregnancies on monotherapy with VPA and CBZ 
revealed that AED polytherapy involving VPA and 
CBZ with diff erent AEDs resulted in a larger propor-
tion of complications and adverse outcomes as com-
pared to monotherapy with those AEDs (Table 4).
Fetal loss
Fetal loss occurred in 9/74 followed-up pregnan-
cies in women with epilepsy. It was due to intrauterine 
death, spontaneous abortion, or stillbirth. In compari-
son to the control group, there was a signifi cantly 
higher number of spontaneous abortions in women 
with epilepsy (p=0.001; D=0.081). Artifi cial abortion 
is legal in Croatia until 10th week of gestation and one 
woman with epilepsy on LTG therapy decided to ter-
minate pregnancy before 10 weeks of gestation for fear 
from adverse eff ects in pregnancy.
Intrauterine growth retardation (IUGR)
In our study, 2 live births were surveyed prenatally 
because of IUGR. Th e fi rst one was exposed to CBZ/
Fig. 1. Diff erences between pregnant women with 
epilepsy having and not having attended preconception 
counseling (c=18.45; DF 1; p<0.05).
Table 2. Antiepileptic therapy in 70 pregnancies according to monotherapy and polytherapy
Total Monotherapy Polytherapy









































AET = antiepileptic therapy
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TPM/PHT and during follow up remained with short 
stature and facial features indicative of the possible 
 fetal anticonvulsant eff ect (Fig. 2A and B), but had 
normal psychomotor development. Th e other one was 
exposed prenatally to GBP. He had atrial septal defect 
discovered after birth and delayed psychomotor devel-
opment. He suff ers from intractable myoclonic epi-
lepsy since infancy. Th e extensive work-up excluded 
chromosomal aberration and inherited metabolic dis-
order, and no specifi c syndrome was revealed by the 
geneticist.
Major congenital malformations, pervasive 
and behavioral aspects, and cognitive abilities
Out of 74 prospectively followed-up pregnancies 
with epilepsy, one child (1/74 or 1.4%) prenatally ex-
posed to GBP had congenital heart defect (atrial sep-
tal defect), while no congenital anomalies at birth were 
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observed in control group (p=0.005, D=0.063). Th e 
above mentioned child exposed to polytherapy with 
CBZ/TPM/PHT, with IUGR, born on term from the 
fourth pregnancy, had dysmorphic facial features in ac-
cordance with fetal anticonvulsant eff ect (Fig. 2). He 
was prospectively followed-up till school age, his psy-
chomotor development is normal and he has no con-
genital malformations. Two boys, one exposed to LTG 
and other one to VPA, had the spectrum of attention 
defi cit hyperactivity disorder. Th e boy exposed to LTG 
had behavioral disturbances accompanied with aggres-
sion, stubbornness and learning diffi  culties. One girl, 
exposed in utero to VPA had attention defi cit hyperac-
tivity disorder, and slight psychomotor and speech de-
velopmental delay. Her mother had one spontaneous 
abortion from pregnancy on VPA and TPM. All three 
children were prospectively followed-up, and they all 
had one-year delay in starting school due to diffi  culties 
in fi ne motor skills, expressive language skills and at-
tention defi cit, and hyperactivity. We had no children 
with clear evidence for autistic spectrum disorder, es-
pecially regarding the group of children prenatally ex-
posed to VPA.
Discussion
Socioeconomic status of epileptic pregnant women
In the current study, healthy pregnant women had 
signifi cantly better levels of education and economic 
Table 4. Outcomes of pregnancies according to 
antiepileptic therapy
62 pregnancies on monotherapy:
LTG: 26 LB, 2 premature deliveries, 3 SA, 
1 artifi cial abortion, 1 intrauterine death
CBZ: 11 LB and 2 SA
PHT: 1 LB
PB: 1 SA and 2 LB
GBP: 1 LB and 1 preterm LB with ASD, 
psychomotor delay and epilepsy
VPA: 6 LB
OXC: 2 LB
8 pregnancies on polytherapy:
VPA/TPM: 2 LB, 1 SA
VPA/CZP: 1 LB
CBZ/PB: 1 SB




4 pregnancies without AED:
All 4 LB
LB = live birth; SB = stillbirth; SA = spontaneous abortion; LTG 
= lamotrigine; CBZ = carbamazepine; PHT = phenytoin; PB = 
phenobarbitone; GBP = gabapentin; VPA = valproic acid; OXC = 
oxcarbazepine; TPM = topiramate; CZP = clonazepam; ASD = 
atrial septal defect; IUGR = intrauterine growth retardation
Fig. 2A and B. Th e boy with short stature and 
craniofacial dysmorphism, prenatally exposed to 
polytherapy with carbamazepine/topiramate/phenytoin 
(with permission of parents).
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status. According to previous reports, fi nancial issue is a 
major problem for patients with epilepsy9. Th e longer 
the duration of epilepsy, the worse the psychological is-
sues are10,11. Epileptic patients have poor education and 
achievement later in life10. Patients who have epilepsy at 
school age have worse learning achievement10. Camp-
bell et al. observed no diff erence in the rate of major 
congenital anomalies between the groups of women 
with low income and education and those with higher 
income and education12. Less deprived women were 
more likely to take preconception FA and less likely to 
have generalized tonic-clonic seizures in pregnancy 
than socially deprived ones. Th ey also were more likely 
to be on monotherapy, less likely to be on VPA, and 
more likely to be on lower doses of the drug compared 
to socially deprived ones12. As diff erences in treatment 
between socioeconomic groups do exist, particularly in 
preconception FA consumption, AED choice and sei-
zure frequency, there should be benefi t from preconcep-
tion counseling for women with low socioeconomic 
status, to discuss AED choice and FA intake and to im-
prove chances for normal pregnancy and delivery.
Smoking
Lower birth weight of newborns of all gestational 
ages was observed in teenage and adult mothers with 
epilepsy who smoked13, as well as negative eff ect of 
maternal smoking on fetal growth14. Our data on 24% 
of pregnant women smoking during pregnancy in 
Croatia are more or less consistent with the recently 
published data on 50% of Croatian pregnant women 
having smoked before pregnancy and 19% continuing 
smoking during pregnancy15. It has already been pro-
posed that women with epilepsy who smoke be warned 
that they possibly are at a substantially higher risk of 
premature contractions and premature labor and deliv-
ery16, and we promote this attitude during counseling 
of women with epilepsy in Croatia. In the group of 
women with epilepsy, there was strong association of 
smoking and early spontaneous abortions; these wom-
en did not take FA during pregnancy, one-third of 
them had seizures during pregnancy, and it was diffi  -
cult to observe only smoking as a variable because of 
the small number of women. Th e lower proportion of 
smokers in the group of women with epilepsy despite 
lower socioeconomic status as compared to healthy 
women could also be the result of our continuous 
counseling about epilepsy and pregnancy.
Folic acid intake and counseling 
of epileptic pregnant women
As the majority of AEDs antagonize folate action, 
children born to women taking antiepileptic therapy 
are at an increased risk of birth defects. Th us, it is sug-
gested that women with epilepsy take FA supplemen-
tation, especially in case of VPA therapy17. Pittschieler 
et al. analyzed 388 pregnancies in 244 patients and 
pregnancies with FA supplementation showed signifi -
cant reduction of spontaneous abortion. In the group 
of women taking VPA as monotherapy, supplementa-
tion of FA had signifi cant benefi t. Other examined 
monotherapies (CBZ, PHE, and PB) known to inter-
fere with FA showed no signifi cant results. Th is study 
confi rmed the prophylactic eff ect of FA supplementa-
tion on spontaneous abortion and the fact that FA 
supplementation should be included in therapy of ev-
ery pregnant epileptic woman, especially those treated 
with VPA18. In the NEAD study of children exposed 
in utero to AED, maternal periconceptional folate in-
take was associated with higher IQ of their children at 
the age of six, but the authors concluded that this fi nd-
ing should be interpreted with caution because peri-
conceptional folate was one of several confounding 
variables, and was established by retrospective mater-
nal interview in the study of neurodevelopmental ef-
fects of AEDs19. In our study, the women with epilepsy 
having received prenatal counseling planned their 
pregnancies in a higher proportion as compared to the 
women with epilepsy without prenatal counseling. 
Sample size in our study was too small to determine 
whether FA protects against birth defects, but our sur-
veillance showed that the prenatally counseled women 
with epilepsy took FA in a higher proportion and had 
signifi cantly less fetal losses and stillbirths. Due to the 
fact that our surveillance was prospective, we can argue 
that preconception counseling in women with epilepsy 
could have resulted in a higher proportion of proper 
FA intake in women with epilepsy, despite the higher 
proportion of planned pregnancies in control subjects.
Seizures
Among pregnant women with epilepsy, the severity 
of the seizure disorder is in concordance with the in-
creased risk of adverse fetal outcomes20 as a conse-
quence using higher AED doses and polytherapy. It 
has been reported that >5 convulsions during preg-
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nancy reduced cognitive levels in newborns21. Th e ef-
fects of AEDs on the child’s cognitive outcome cannot 
be explained only by the severity of the maternal sei-
zure disorder, as assessed in the analysis for the NEAD 
study and additional research is suggested. Th e in-
creased volume of distribution and the hepatic me-
tabolism of AEDs, along with decreased compliance 
during pregnancy and self-initiative interruption of 
AED intake because of concerns about their eff ects on 
the fetus, lead to an increase in seizure frequency dur-
ing pregnancy in women with epilepsy. Seizures in 
women with epilepsy are observed in as many as 17%-
40% of pregnancies22,23. In our study, 40% of women 
with epilepsy had seizures during pregnancy, but ow-
ing to close drug monitoring, AED increase (especial-
ly LTG) or therapy switch we had no epileptic status 
and no signifi cantly increased percentage of complica-
tions in women with seizures during pregnancy, except 
for the higher number of cesarean sections.
Mode of delivery and anthropometric measurements
About 5% to 25% of deliveries in Croatia end up 
with cesarean section, depending on the hospital level 
and pathology of the population served. Th e most fre-
quent specifi c indications for cesarean section in Croa-
tia are cesarean section in previous pregnancy, pro-
longed delivery, fetal dystocia, and cardiotocography 
fi ndings that require emergency delivery. Since both of 
our groups included women followed-up at a tertiary 
center where there is usually a higher percentage of 
cesarean sections, the higher percentage recorded in 
our study is not surprising. Although we had no data 
on the specifi c reasons of cesarean section in every 
woman, the fact is also that cesarean section performed 
upon patient request has been increasing in Croatia 
and in nearby countries24. Th e higher risk of Apgar 
score <7 in deliveries of women with epilepsy was also 
noticed by some authors25. It was not possible to iden-
tify specifi c factors for lower Apgar score in this study, 
except for preterm deliveries also resulting in lower 
birth weight.
Fetal loss
Since pregnancy loss can occur very early in preg-
nancy, it is hard to estimate the true fetal loss in preg-
nant women. Nine fetal losses (9/74 or 11.4%) in the 
epileptic group in the current study (7 spontaneous 
abortions and 2 stillbirths) were higher than some pre-
viously published data18,25. Th omas et al. showed a 
higher rate among women with epilepsy (4%) than in 
controls (2%). Th e risk was higher in women on val-
proate (8%) than in those on other AEDs (1%-6%)25. 
Pittschieler et al. report results of a non-randomized, 
partly retrospective study with 10% of spontaneous 
abortions in women with epilepsy and a lower range of 
spontaneous abortion among those using FA supple-
mentation18. Our results also suggested a signifi cantly 
higher risk of spontaneous abortion in epileptic preg-
nancies as compared to controls. One important result 
was a signifi cantly lower risk of spontaneous abortion 
in women with epilepsy having received preconception 
counseling. Women in this group also took FA in a 
higher percentage than non-counseled ones. Th e group 
of women with epilepsy had a signifi cantly higher FA 
supplementation as compared to controls, despite the 
higher proportion of planned pregnancies in controls. 
We can only suppose that preconception counseling 
enabled higher FA intake in women with epilepsy and 
possibly infl uenced the reduced risk of fetal loss in 
their pregnancies. Th e fact that a large proportion of 
fetal loss in general population is associated with chro-
mosomal abnormalities and many occur too early to be 
recognized makes it diffi  cult to estimate the true inci-
dence of fetal loss due to epilepsy/AED. Furthermore, 
there are no larger studies with consistent data on 
chromosomal aberrations in pregnancies of women 
with epilepsy26,27. We can assume that the signifi cant 
diff erence in fetal loss between these two prospectively 
followed-up groups was in connection with epilepsy 
and its potential to cause complications during preg-
nancy.
Intrauterine growth retardation
Th ere are some data that AEDs can infl uence fetal 
growth suggesting an increasing risk of small for ges-
tational age newborns exposed to AED in utero28. 
Some studies have shown that CBZ and VPA as 
monotherapy during pregnancy reduce the mean body 
weight-adjusted head circumference and that AED 
polytherapy increases the rate of microcephaly. Ac-
cording to these studies, the possible signifi cance for 
further development of the child is uncertain and 
should be explored29,30. In our study, two live births 
were surveyed prenatally because of IUGR. Th e fi rst 
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one was exposed to CBZ/TPM/PHT and remained 
with short stature during follow up, but also with facial 
dysmorphism due to the fetal anticonvulsant eff ect 
(Fig. 2A and B). Th e second case of IUGR was ex-
posed to GBP, with cardiac anomaly (atrial septal de-
fect) discovered after birth, had delayed psychomotor 
development during follow up, and started to suff er 
from intractable myoclonic epilepsy in infancy. Karyo-
type was normal in both cases.
Congenital malformations, pervasive and behavioral 
aspects, and cognitive abilities
Th e extensive metabolic and genetic work-up found 
no specifi c syndrome in the boy prenatally exposed to 
GBP with psychomotor and somatic delay, generalized 
epilepsy and congenital heart anomaly. GBP has no 
specifi c pattern of congenital anomalies and data sup-
port the safety of GBP use in pregnancy; however, the 
number of exposures to date is still small31. Th e rate of 
2.7% of major congenital anomalies in our group of 
women with epilepsy was in accordance with the rate of 
major congenital malformations in general population, 
but it was still higher in the group of women with epi-
lepsy as compared to healthy controls with no congeni-
tal malformations found at birth (c2-test=9.514; DF=2; 
signifi cance level p=0.0086; contingency coeffi  cient 
0.201).
Th e boy exposed prenatally to CBZ/TPM/PHT 
(Fig. 2A and B) was born from irregularly controlled 
pregnancy at another institution. Th e mother came to 
our institution in 16th week of pregnancy, when we ex-
cluded CBZ from therapy and she remained on TPM 
and PHT, seizure free during pregnancy. Characteris-
tic dysmorphic features have been described so far 
with fetal exposure to phenytoin, valproate, and CBZ. 
Fetal phenytoin is said to be associated with hyper-
telorism, broad nasal bridge, short nose, and facial hir-
sutism, while fetal CBZ face includes epicanthic folds, 
short nose, long philtrum, and upward slanting palpe-
bral fi ssures, as in our patient mentioned above32-34. 
Although distinctive phenotypes have been described 
for diff erent anticonvulsants, there is an overlap in 
both facial dysmorphic features and malformations.
Fetal anticonvulsant syndromes also consist of 
 behavioral phenotype34. Of the three children with at-
tention defi cit/hyperactivity disorder (ADHD) in our 
study, the boy exposed prenatally to LTG improved his 
social skills with time and he attends regular school, 
but the other two children prenatally exposed to VPA 
are still under surveillance, psychotherapy and reha-
bilitation. Th e recently published data implicate that 
prenatal exposure to valproate can be associated with 
autistic spectrum disorder in the off spring, even after 
adjusting for maternal epilepsy35. It is recommended 
that this important information be shared with wom-
en of childbearing potential within the counseling 
when discussing treatment options that include val-
proate36,37. Taking this into account, in our group of 
women on VPA treatment we also balanced against 
the treatment benefi ts for women requiring valproate 
for epilepsy control and made therapy switch where 
possible (Table 4).
According to the NEAD study, fetal VPA exposure 
has dose-dependent associations with reduced cogni-
tive abilities across a range of domains at 6 years of age 
and the positive association of periconceptional folate 
with IQ was consistent with other recent studies19. In 
this study, the mother of the child with mental delay 
and mothers of children with ADHD did not take FA 
periconceptionally, nor did the mother of the boy with 
fetal anticonvulsant syndrome. Bromley et al. com-
pared the prevalence of neurodevelopmental disorders 
diagnosed in 415 children exposed in utero to diff erent 
AEDs, and autistic spectrum disorder was the most 
frequent diagnosis. No signifi cant increase was found 
among children exposed to CBZ or LTG38. An accu-
mulation of evidence so far demonstrates that the risks 
associated with prenatal sodium VPA exposure include 
an increased prevalence of neurodevelopmental disor-
ders39,40. Th e European Medicines Agency (EMA) has 
strengthened warnings on the use of VPA in women 
and girls (EMA November 21, 2014). As these restric-
tions have been incorporated in the amended Sum-
mary of Product Characteristics (SmPC) and package 
leafl ets in all EU member states, the Commission of 
European Aff airs of the International League Against 
Epilepsy (CEA-ILAE) and the European Academy 
of Neurology (EAN) have appointed the Task Force 
and published recommendations for clinical use of 
VPA in the treatment of girls and women with epi-
lepsy in the context of these new restrictions41. Th ese 
Task Force’s recommendations include the following: 
1) where possible, valproate should be avoided in 
women of childbearing potential; 2) the choice of 
treatment for girls and women of childbearing poten-
Snježana Miškov et al. Management of epilepsy and pregnancy in Croatia
Acta Clin Croat, Vol. 55, No. 4, 2016 545
tial should be based on a shared decision between cli-
nician and patient, and where appropriate, the patient’s 
representatives. Discussions should include careful 
risk-benefi t assessment of reasonable treatment op-
tions for the patient’s seizure or epilepsy type; 3) for 
seizure (or epilepsy) types where valproate is the most 
eff ective treatment, the risks and benefi ts of valproate 
and other treatment alternatives should be discussed; 
4) valproate should not be prescribed as a fi rst-line 
treatment for focal epilepsy; 5) valproate may be of-
fered as a fi rst-line treatment for epilepsy syndromes 
where it is the most eff ective treatment, including id-
iopathic (genetic) generalized syndromes associated 
with tonic-clonic seizures; 6) valproate may be off ered 
as a fi rst-line treatment in situations where pregnancy 
is highly unlikely (e.g., signifi cant intellectual or phys-
ical disability); and 7) women and girls taking valpro-
ate require regular follow-up for ongoing consider-
ation of the most appropriate treatment regimen41.
For newer AEDs, one multicenter, observational 
prospective cohort study conducted by our ENTIS 
colleagues in 2016 demonstrated a signal for an in-
creased risk of major birth defects after fi rst trimester 
exposure to pregabalin, but these results need confi r-
mation through independent studies42. Newer data 
also suggest that lamotrigine and levetiracetam are 
 associated with a relatively low risk for both anatomic 
and developmental adverse eff ects, although further 
studies are needed for these and other AEDs43.
Th e model of management of epilepsy 
in pregnancy in Croatia
Croatia is a south-eastern European country, with 
about 4,500,000 inhabitants. Th e incidence, prevalence 
and mortality of epilepsy vary across countries with 
diff erent economies44, and according to Bielen et al., it 
is likely that the prevalence of active epilepsy in Croa-
tia is between 4.8 and 5.5/100045. In Croatia, neurolo-
gists and pediatric neurologists are usually taking care 
of the people with epilepsy and general practitioners 
follow their advice and proceed with drug prescrip-
tions. Th e usual frequency of outpatient visits to ter-
tiary centers is every 3-6 months, depending on the 
severity of epilepsy. Our clinical hospital center has the 
3rd largest maternity hospital in the country, with 3200 
deliveries per year. If we consider the previous fact that 
1 of 250 embryos/fetuses are exposed to AED1, we can 
expect about 13 newborns exposed in utero to AEDs in 
our maternity hospital each year. Our health profes-
sionals working in the maternity hospital frequently 
have some issues with pregnant women with epilepsy. 
In order to improve the quality of management in such 
pregnancies, we have developed close collaboration 
among diff erent specialists (gynecologists, neurolo-
gists, neonatologists and pediatric neurologists/geneti-
cists). Th is collaboration has resulted in a prospective 
registry of pregnant women with epilepsy dating from 
2003, and in scientifi c collaboration with institutions 
such as the Institute for Medical Research and Occu-
pational Health in Croatia. After formation of the 
Teratology Information Service at the Department of 
Pediatrics in 2004 (TIS Zagreb, since 2010 at Srebrn-
jak Children’s Hospital) and the Center for Counsel-
ing for Epilepsy and Pregnancy at the Clinical De-
partment of Neurology, Sestre milosrdnice University 
Hospital Center, Sestre milosrdnice, women with epi-
lepsy can be prospectively followed-up, off ered pre-
pregnancy counseling at the proper time, prospectively 
follow-up their pregnancy and children, from the neo-
natal period till school age or after it if needed.
Conclusion
Our model of the integrative management of preg-
nancy and epilepsy includes close collaboration among 
clinical experts in neurology, gynecology, pediatrics 
and primary health care professionals (Fig. 3). Every 
woman with epilepsy in generative age should receive 
preconception counseling. Women with epilepsy 
should be encouraged to attend pre-pregnancy coun-
seling during their ordinary follow up visits, using 
tickets from their primary health professionals, or as 
an emergency expertise if needed. Pregnant woman 
with epilepsy has to be counseled about the risk that 
her disease can bring, but also about the possibilities to 
minimize the risk by appropriate treatment, good con-
trol of epilepsy, quality of nutrition, vitamin intake, 
screening for congenital anomalies, and careful sur-
veillance of pregnancy and delivery. Women with epi-
lepsy that smoke should be counseled that they possi-
bly have a substantially increased risk of premature 
contractions and premature labor and delivery.
Planned pregnancy with periconceptional FA in-
take increases the possibility of favorable outcome of 
pregnancy in women with epilepsy. Monotherapy and 
the lowest possible dose of AED in pregnant women 
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with epilepsy can lower the risk of congenital anoma-
lies. Of newer AEDs, lamotrigine has the best docu-
mented data on the use in pregnancy. After being ex-
posed to AED, no termination of pregnancy is indi-
cated, but prenatal surveillance is needed as in other 
AED exposures, including alpha-fetoprotein screen-
ing and US examinations (anomaly scan). Frequent 
monitoring of LTG (and OXC) concentrations (at 
least monthly) is very helpful, with dose adjustment 
before, during and after pregnancy. Individual ap-
proach to every pregnant woman is advised because of 
inter-individual variations in pharmacokinetics.
Our study was limited by the small number of 
pregnancies on the same AED, but the intention of 
this study was not to analyze the eff ect of each AED 
on the fetus, but the benefi ts of the integrative model 
of pregnancy follow up in epilepsy.
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Sažetak
HRVATSKI MODEL INTEGRATIVNE PROSPEKTIVNE SKRBI TRUDNOĆA 
U ŽENA S EPILEPSIJOM
S. Miškov, R. Gjergja Juraški, I. Mikula, S. Bašić , M. Bošnjak Pašić, V. Košec, Z. Sabol, A. Fučić, T. Sajko i V. Bašić Kes
Epilepsija je najčešća neurološka komplikacija u trudnoći. Žene s epilepsijom imaju veći rizik za komplikacije u trudnoći. 
U Hrvatskoj žene s epilepsijom obično prate neurolozi u tercijarnim centrima prema mjestu njihova boravka. Mi smo 
 prospektivno pratili trudnoće u žena s epilepsijom i u zdravih kontrolnih trudnica te analizirali čimbenike odgovorne za 
 ishode trudnoća i razvoj njihove djece. Zdrave trudnice su imale višu razinu obrazovanja i ekonomskog statusa, ali su žene s 
epilepsijom uzimale folnu kiselinu u višem postotku nego zdrave trudnice zahvaljujući pravodobnom predkoncepcijskom 
savjetovanju. Komplikacije za vrijeme trudnoće ovisile su o broju antiepileptičnih lijekova i kontroli epilepsije. Zamijetili smo 
određene bihevijoralne i kognitivne aspekte u djece izložene in utero valproičnoj kiselini, što zahtijeva daljnje praćenje. Stopa 
kongenitalnih malformacija nije bila povišena. U zaključku, ženama s epilepsijom trebali bismo omogućiti predkoncepcijsko 
savjetovanje o rizicima u trudnoći, ali i o mogućnostima kako značajno smanjiti taj rizik. Predstavili smo model integrativne 
prospektivne skrbi trudnica s epilepsijom koji se temelji na bliskoj suradnji različitih kliničkih eksperata u Hrvatskoj, u cilju 
osiguranja promptnog  savjetovanja i pravodobne intervencije.
Ključne riječi: Epilepsija; Trudnoća; Antiepileptici; Epileptični napadaji; Kongenitalne malformacije
